More than a few pharmaceutical companies have pushed through a slew of price hikes as 2018 gets underway, but one of AbbVie’s increases stands out among the rest.
According to a Fierce Pharma report, AbbVie’s 9.7 percent price hike on Humira, its megablockbuster drug used to treat arthritis, Crohn’s disease, plaque psoriasis and other conditions, could tack on more than $1 billion to the U.S. drug bill this year.
None of the companies mentioned in the report exceeded a 10 percent price hike.
The following is a rundown provided in the Fierce Pharma report:
- Pfizer: 116 price hikes between 3 and 9.46 percent;
- Novartis: 17 price hikes between 2.9 and 9.9 percent;
- AstraZeneca: 18 price hikes between 1.5 and 9.9 percent;
- Eli Lilly: 12 price hikes between 1.5 and 9.91 percent;
- Sanofi: 11 price hikes between 1.9 and 8.53 percent;
- Bristol-Myers Squibb: Six price hikes between 1.5 and 7.9 percent;
- AbbVie: Five price hikes between 8 and 9.7 percent; and
- GlaxoSmithKline: Four price hikes between 3.11 and 9 percent.